Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
==== Sublingual ==== Sublingual administration is fulfilled by placing the drug between the tongue and the lower surface of the mouth. The sublingual mucosa is highly permeable and thereby provides access to the underlying expansive network composed of capillaries, leading to rapid drug absorption.
1. A mobilization of intracellular Ca2+ ions is closely connected with a biological activity of sarafotoxins; 2. The blockers specific to Ca2+ channels, such as verapamil or ninodipine, have no effect on binding capability of 125I-SRTX-b; 3. The hydrolysis of phosphoinositides is induced by binding of SRTXs. Above characteristics suggest that sarafotoxins (and endothelins) use the phosphoinositide signal transduction pathway via specific receptors coupled to G protein, which seems to activate type C and D phospholipases. However, distinct and widespread subtypes of glycosylated receptors are recognized functionally by SRTXs and ETs. As all of the three isoforms of endothelins and sarafotoxins interplay with the same affinity, ETB-R appears less selective than ETA-R. Nonetheless, the variable tissue distribution of the endothelin-binding sites, and the different biological effects demonstrated within different organs, indicate the possibility of an existence of other endothelin/sarafotoxin subtypes of receptors. Therefore, the ability of the Egyptian mongoose to resist very high concentrations of SRTX-b may be due to presence of an additional family of binding sites, located in the cardiovascular tissue, differentiating ET-1 and SRTX-b.
=== Pharmacodynamics === 3-HO-PCP acts as a high-affinity uncompetitive NMDA receptor antagonist via the PCP site with a Ki of 30 nM. It has a higher affinity than PCP, which has a Ki of 250 nM for this site (eight-fold higher). Unlike many other arylcyclohexylamines, including close analogues such as 3-Chloro-PCP and 3-MeO-PCP, 3-HO-PCP has a high affinity for various opioid receptors. It has a Ki value of 39–60 nM for the μ-opioid receptor, 140 nM for the κ-opioid receptor, and 42 nM for the σ1 receptor. It has weaker activity at the δ-opioid receptor, with a Ki of 2,300 nM.
Sources: en.wikipedia.org
== Alternative remedies == The medieval Bald's Leechbook recommended treating chilblains with a mixture of eggs, wine, and fennel root. A modern-day home remedy is to put garlic on the chilblains. Other herbal remedies supposed to be vasodilating, rubifacient, and warming, have been recommended.
Among the earliest reports of MOF-based catalysis was the cyanosilylation of aldehydes by a 2D MOF (layered square grids) of formula Cd(4,4′-bpy)2(NO3)2. This investigation centered mainly on size- and shape-selective clathration. A second set of examples was based on a two-dimensional, square-grid MOF containing single Pd(II) ions as nodes and 2-hydroxypyrimidinolates as struts. Despite initial coordinative saturation, the palladium centers in this MOF catalyze alcohol oxidation, olefin hydrogenation, and Suzuki C–C coupling. At a minimum, these reactions necessarily entail redox oscillations of the metal nodes between Pd(II) and Pd(0) intermediates accompanying by drastic changes in coordination number, which would certainly lead to destabilization and potential destruction of the original framework if all the Pd centers are catalytically active. The observation of substrate shape- and size-selectivity implies that the catalytic reactions are heterogeneous and are indeed occurring within the MOF. Nevertheless, at least for hydrogenation, it is difficult to rule out the possibility that catalysis is occurring at the surface of MOF-encapsulated palladium clusters/nanoparticles (i.e., partial decomposition sites) or defect sites, rather than at transiently labile, but otherwise intact, single-atom MOF nodes. "Opportunistic" MOF-based catalysis has been described for the cubic compound, MOF-5.
==== Memorial ceremony for the Martyrs of San Juan de Wilson ==== At 6:30pm on March 5, 1870, San Andrés Lodge No. 3, in Havana, held a memorial ceremony to observe Masonic funeral rites for the deceased Grand Master Andrés Puente. Despite the fact that certain members of the Lodge were afraid that a memorial gathering would put their lives in danger, nevertheless more than 100 people made a fully-packed temple that night, with all Lodge members present. The local police, however, had also known that there would be a memorial that night. When the temple was full, the armed and uniformed police mustered in the street out front of the Lodge. As the police were getting into formation, local citizens gathered behind them and grew into a large mob, chanting and crying out: "Kill the conspirators, death to the Cuban Council!" When the police breached the building, the Outside Guard informed Worshipful Master Nicolas Dominguez Cowan that the police were on the stairs. Cowan addressed the Freemasons: "Do not be alarmed, my dear brethren, our fate, whatever it may be, we must face with courage; we must save our charter above everything else." Edward Godwin, a government employee at the local customs house, escaped the Lodge with the charter and brought it to the safety at a house belonging to another Freemason, where he stashed it. Of the over 100 people in the building that night, over 40 of them were arrested and taken to prison. Some of the members were able to evade capture. Those forty or more Freemasons who were arrested that night were imprisoned for one hundred days.
=== Anti-inflammatory uses === One of its therapeutic effects is its ability to reduce inflammatory responses by decreasing synthesis of pro-inflammatory cytokines and inhibiting inflammatory signaling pathways, such as NF-kB. Excessive inflammation not only further damages tissue but also slows the healing process, making PDRN's anti-inflammatory activity as a key feature of its effects. PDRN showed modulation of markers connected to chronic low-grade inflammation (also referred to as inflammaging) and age-related deterioration, suggesting these properties may enhance tissue homeostasis under conditions of prologed stress.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.